mRNA Display Services

Rx Biosciences specializes in mRNA display library screening, a process that involves constructing and testing libraries made up of diverse peptide sequences, cDNAs, and antibodies. Each library includes specific elements such as T7 RNA polymerase sites, ribosome binding sites, puromycin binding sites, and RNA stability motifs to ensure reliable performance.

The process begins with in vitro transcription, during which Rx Biosciences synthesizes mRNA and attaches it covalently to puromycin. This setup creates a stable link between the mRNA and the protein it encodes. Next, researchers carry out the translation using either E. coli or eukaryotic cell lysates, supported by tRNA, buffer, and high concentrations of Mg++.

After forming the polypeptide–mRNA–puromycin complex, the team purifies it and immediately mixes it with the target molecule. Through several rounds of screening, Rx Biosciences selectively isolates and enriches the target-peptide-mRNA-ribosome complexes. The team then extracts the RNA, performs reverse transcription, and clones the resulting cDNA into a vector. Following this, they sequence and translate the clones to identify the corresponding amino acid sequences of the ligands.

Thanks to mRNA display library screening, Rx Biosciences can screen peptide, protein, and antibody libraries with exceptional diversity—up to 10¹⁴–10¹⁵ variants. As a result, the likelihood of identifying high-affinity binders against a wide variety of targets increases dramatically.

Rx Biosciences uses the ribosome display technique to screen highly diverse peptide, protein, and antibody libraries—reaching up to 10¹⁴–10¹⁵ variants. As a result, they dramatically improve the chances of discovering high-affinity binders for a broad spectrum of targets.

Service Highlights
Request a Quote

Ready to start your project? Send us a message and we’ll provide you with a customized quotation for your project’s requirements. 

Request a Quote